HBM Holdings Limited announced that Nona Biosciences (Suzhou) Co. Ltd. (Nona Biosciences) and AstraZeneca have entered into a license and option agreement for preclinical monoclonal antibodies that will be used to create targeted therapies in oncology. Pursuant to the Agreement, Nona Biosciences shall receive: upfront payments of USD 19 million upon completion of the transaction; near-term milestone payments of USD 10 million; up to USD 575 million milestone payments upon achieving specified development, regulatory and commercial milestones; and tiered royalties on net sales.

In addition, Nona Biosciences is eligible to receive payments for the option programs should AstraZeneca exercise these options. The Agreement marks a significant milestone in the business development of the company's Harbour Mice® Platform, validating the potential of the company's technology platforms and innovation capabilities. The company will also leverage on this opportunity to further strengthen its global cooperation network through its innovative collaboration model and maximize the scientific and commercial value of the company's technology platforms.